Immediate Oncology Intelligence
Imagene leverages AI to profile within minutes a broad range of cancer biomarkers from the biopsy image alone
Imagene leverages AI to profile within minutes a broad range of cancer biomarkers from the biopsy image alone
Imagene announces LungOI, the first AI-based NSCLC Molecular Panel for immediate cancer biomarker profiling
Read more
To empower physicians with immediate oncology intelligence to facilitate optimal treatment for more cancer patients.
Lawrence J. Ellison Institute for Transformative Medicine
"This is a breakthrough technology that has been tested in deep collaboration with the physicians of our pathology lab"
Sheba Medical Center
“Unfortunately, we are so used to waiting a long time for molecular cancer testing while patients deteriorate, that such a breakthrough technology, enabling treatment initiation within a day is exceptional.”
Tel Aviv Sourasky Medical Center
“The pathology dept. at Ichilov participates in research and development of many new and advanced technologies, but it is rarely that we see a direct and meaningful impact on patients’ lives. We are excited about the opportunity to partner with Imagene to improve quality of care and impact patients’ lives.”
Tel Aviv Sourasky Medical Center
"Cancer diagnosis focuses on pathological and molecular testing. I believe that no structure and assumptions should become a barrier to personalized treatment. Imagene brings the potential of accurate, fast, actionable, profiling to all cancer patients."
Shaare Zedek Medical Center
lmagene's state-of-the-art deep learning models have the capabilities of searching for all present phenotypic alterations and empowering the reporting of meaningful insights.
We make no assumptions. our models rely on prospective data and unsupervised learning to provide the highest sensitivity and specificity rates.
“Imagene’s technology can unlock precise and crucial information in real-time, changing the way cancer is diagnosed and treated.”